← All trials
NCT04803747
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2021
- Primary completion
- Nov 15, 2021
- Completion date
- Nov 15, 2021
- First posted
- Mar 18, 2021
- Last posted
- Apr 30, 2021
- Enrollment
- 8320
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of ManitobaLead sponsor
- University of OttawaCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- University of ManitobaReponsible party - principal investigator
- University of ManitobaOverall official - principal investigator
- Health Sciences Centre Foundation, ManitobaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.